TrialJAMA dermatology2026

Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.

Aaron R Mangold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.